CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,128 shares of the company’s stock after acquiring an additional 2,478 shares during the period. Oppenheimer & Co. Inc.’s holdings in CRISPR Therapeutics were worth $1,603,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CRSP. Global Trust Asset Management LLC boosted its position in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC grew its stake in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics during the 2nd quarter valued at about $35,000. Finally, Denver PWM LLC acquired a new position in CRISPR Therapeutics during the second quarter worth about $45,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock valued at $1,917,679 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital decreased their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Trading Up 0.9 %

Shares of CRSP opened at $47.25 on Monday. The stock’s fifty day simple moving average is $47.88 and its 200 day simple moving average is $52.03. CRISPR Therapeutics AG has a twelve month low of $43.42 and a twelve month high of $91.10. The firm has a market capitalization of $4.03 billion, a P/E ratio of -16.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the company posted ($1.41) EPS. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.